Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

Medigene AG. (1/17/19). "Press Release: Medigene Participates at Four Upcoming Conferences". Martinsried.

Organisations Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
  Organisation 2 Guggenheim (Group)
Products Product TCR engineered T-cells
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Persons Person Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)
  Person 2 Pinkernell, Kai (Medigene 201602– CMO before Miltenyi Biotec + Cytori Therapeutics)
     


Martinsried/Munich - Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced its participation at the following upcoming investor and scientific conferences:

Harald von Boehmer Midwinter Conference 2019 International Immunobiology Symposium
Date: 19 - 23 January 2019
Location: Seefeld in Tirol, Austria

Guggenheim Healthcare Talks/Oncology Day
Date: 14 February 2019
Location: New York, USA

13th ODDO BHF German Conference
Date: 19 - 20 Februar 2019
Location: Frankfurt, Germany

CAR-TCR Summit Europe 2019
Date: 25 - 27 Februar 2019
Location: London, UK
Prof. Dolores Schendel, CEO and CSO of Medigene, will give a presentation on 26 February entitled "Next generation TCR-T cell therapies can offer improved safety and enhanced efficacy" and Dr. med. Kai Pinkernell, CMO and CDO of Medigene will talk about "Obtaining clinical trial authorisation for TCR-modified T cells in Germany" on 27 February.


Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com


This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.


Contact

Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

   
Record changed: 2019-02-12

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Medigene (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top